Lilly collaborates with UnitedHealth to study Covid-19 antibody
The study plans to enrol up to 500,000 subjects of which at least 5,000 are expected to get bamlanivimab therapy. Credit: Willfried Wende from Pixabay.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more